Platinum-based drugs are an important class of antineoplastic agents in NEET PG pharmacology.
Members of the platinum group:
1. Cisplatin (1st generation) -- prototype; testicular, ovarian, head and neck, cervical, lung, bladder cancers
2. Carboplatin (2nd generation) -- less nephrotoxic; ovarian, lung cancers
3. Oxaliplatin (3rd generation) -- colorectal cancer (FOLFOX/CAPOX regimens)
Mechanism:
After entering the cell, the chloride leaving groups are displaced by water (aquation), forming a reactive $\text{Pt}^{2+}$ species. This covalently crosslinks DNA strands, primarily forming $\text{d(GpG) intrastrand crosslinks}$, blocking DNA replication and transcription, and triggering apoptosis.
Toxicity of Cisplatin:
- Nephrotoxicity (dose-limiting; prevented by IV saline hydration + amifostine)
- Ototoxicity (irreversible high-frequency hearing loss)
- Peripheral neuropathy
- Most emetogenic agent -- requires 5-HT3 antagonist + NK1 antagonist prophylaxis
- Hypomagnesemia, hypokalemia
Carboplatin vs Cisplatin:
Carboplatin has less nephrotoxicity and ototoxicity but more myelosuppression.
\[\boxed{\text{Cisplatin}}\]